Black Diamond Therapeutics
BDTX
50 hedge funds and large institutions have $40.6M invested in Black Diamond Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 9 closing their positions.
4,400% more call options, than puts
Call options by funds: $45K | Put options by funds: $1K
7% more capital invested
Capital invested by funds: $37.8M → $40.6M (+$2.82M)
1.03% more ownership
Funds ownership: 57.89% → 58.92% (+1%)
15% less funds holding
Funds holding: 59 → 50 (-9)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.09M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$791K |
| 3 |
Millennium Management
New York
|
+$579K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$96.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$545K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$496K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$337K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$326K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$176K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Belvedere Trading
Chicago,
Illinois
| – | -$31.1K | -17,295 | Closed |
|
52
Jane Street
New York
| – | -$23.2K | -12,914 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$6.18K | -3,433 | Closed |
|
|
BAM
54
Belpointe Asset Management
Reno,
Nevada
| – | -$2.16K | -1,201 | Closed |
|
55
Citigroup
New York
| – | -$243 | -135 | Closed |
|
|
IRC
56
Investors Research Corp
Atlanta,
Georgia
| – | -$54 | -30 | Closed |
|
BDTX Hedge Fund Activity: Q1 2023 in Review
50 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2023, worth a combined $40.6M — up 7.5% from $37.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BDTX and 1 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was EcoR1 Capital, adding an estimated $2.09M. The largest seller was BlackRock, cutting an estimated $545K.
- 50 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2023, down from 59 in Q4 2022.
- Funds reported $40.6M of Black Diamond Therapeutics stock for Q1 2023, up 7.5% quarter-over-quarter.
- 1 fund opened new Black Diamond Therapeutics positions in Q1 2023 and 9 closed out, a net change of -8 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2023 was EcoR1 Capital, an estimated $2.09M added.
- The largest Black Diamond Therapeutics seller in Q1 2023 was BlackRock, an estimated $545K sold.
Based on aggregated 13F filings for Q1 2023.